✦ LIBER ✦

Transformed essential thrombocytosis with a JAK2 V617F mutation relapsing as JAK2 mutation-negative leukaemia after allogeneic stem cell transplantation

✍ Scribed by Au, W Y; Fung, A; Lam, K Y; Lie, A K; Liang, R; Kwong, Y L

Book ID: 110015109
Publisher: Nature Publishing Group
Year: 2006
Tongue: English
Weight: 83 KB
Volume: 38
Category: Article
ISSN: 0007-1188
DOI: 10.1038/sj.bmt.1705482

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Eradication of JAK2 V617F mutation after

Eradication of JAK2 V617F mutation after allogeneic transplantation in a patient with myelofibrosis with myeloid metaplasia

✍ Fiorini, A; Reddiconto, G; Farina, G; Marietti, S; Palladino, M; Chiusolo, P; Le 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 100 KB

Clearance of the Janus kinase 2 (JAK2) V

Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia

✍ Guillermo J. Ruiz-Argüelles; Javier Garcés-Eisele; Virginia Reyes-Núñez; Guiller 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 2 views

TG101348, a JAK2-selective antagonist, i

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

✍ Lasho, T L; Tefferi, A; Hood, J D; Verstovsek, S; Gilliland, D G; Pardanani, A 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 103 KB

Relapse of postpolycythemia myelofibrosi

Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation

✍ Benjamini, O; Koren-Michowitz, M; Amariglio, N; Kroger, N; Nagler, A; Shimoni, A 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 86 KB

A new MALDI-TOF-based assay for monitori

A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD)

✍ Maya Koren-Michowitz; Avichai Shimoni; Asaf Vivante; Luba Trakhtenbrot; Gideon R 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 343 KB